The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval and the FDA has approved subcutaneous formulations of key monoclonal antibodies including Merck's Keytruda and Lunsumio for easier administration. Additional positive opinions include a fixed-ratio insulin icodec/semaglutide combination, advancing treatment options with improved patient convenience.